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SUMMARY
Alzheimer’s disease (AD) is characterized by cogni-
tive decline and 5- to 10-fold increased seizure inci-
dence. How seizures contribute to cognitive decline
in AD or other disorders is unclear. We show
that spontaneous seizures increase expression of
DFosB, a highly stable Fos-family transcription fac-
tor, in the hippocampus of an AD mouse model.
DFosB suppressed expression of the immediate
early gene c-Fos, which is critical for plasticity
and cognition, by binding its promoter and trig-
gering histone deacetylation. Acute histone deace-
tylase (HDAC) inhibition or inhibition of DFosB
activity restored c-Fos induction and improved
cognition in AD mice. Administration of seizure-
inducing agents to nontransgenic mice also re-
sulted in DFosB-mediated suppression of c-Fos,
suggesting that this mechanism is not confined to
AD mice. These results explain observations that
c-Fos expression increases after acute neuronal
activity but decreases with chronic activity. More-
over, these results indicate a general mechanism
by which seizures contribute to persistent cognitive
deficits, even during seizure-free periods.
INTRODUCTION
Alzheimer’s disease (AD) is the most prevalent type of dementia
among the elderly and is associated with prominent impairments
in hippocampal memory (Burgess et al., 2002; Selkoe, 2002;
Tulving and Markowitsch, 1998). Many current treatments are
aimed at preventing disease progression in at-risk individuals
or early in disease. A central component of these therapeutic ef-
forts is the prevention of cognitive decline. Therefore, compre-
hensive understanding of the neuronal and network alterations
associated with cognitive dysfunction in AD is critical to enable
development of effective therapeutics.
It is becoming increasingly clear that network dysfunction,
which can manifest as seizures and epileptiform activity, plays
a contributing role in AD-related cognitive deficits. AD is associ-
ated with a 5- to 10-fold increased risk in seizures (Amatniek
et al., 2006; Larner, 2010; Lozsadi and Larner, 2006). This rate
may be underestimated due to the incidence of subclinical
epileptiform activity and non-convulsive seizures, which in a ma-
jority of cases precede or coincide with the diagnosis of amnes-
tic mild cognitive impairment or AD (Vossel et al., 2013). A recent
prospective study found that 42.4% of AD patients with no clin-
ical history of seizures exhibited subclinical epileptiform activity,
and the presence of such activity was associated with faster
rates of cognitive decline (Vossel et al., 2016). Furthermore, mul-
tiple mouse models of AD exhibit epileptiform activity (Chin and
Scharfman, 2013; Kam et al., 2016; Minkeviciene et al., 2009;
Palop et al., 2007; Palop and Mucke, 2009). Because patients
with intractable epilepsy and mouse models of epilepsy display
hippocampal memory deficits (Hermann et al., 2006; Hoppe
et al., 2007; Stafstrom et al., 1993), the epileptiform activity asso-
ciated with AD may contribute to cognitive deficits as well.
Indeed, antiepileptic drug treatment reduces network dysfunc-
tion and improves hippocampus-dependent cognition in prodro-
mal AD patients and mouse models of AD (Bakker et al., 2012;
Sanchez et al., 2012). However, the mechanisms by which sei-
zures induce persistent cognitive deficits in AD and epilepsy
are poorly understood, particularly because seizure frequency
is often not high.
Neuronal activity alters expression of many genes in the hip-
pocampus, with important consequences for learning and
memory. One of the most widely studied is Fos, a gene whose
protein product, c-Fos, is critical for synaptic plasticity and hip-
pocampal memory (Fleischmann et al., 2003; He et al., 2002;
Tischmeyer and Grimm, 1999). Recent studies demonstrated
that neuronal activity induces formation of DNA double-strand
breaks (Madabhushi et al., 2015), including within the pro-
moters of early-response genes, including Fos, which facilitates
their expression (Madabhushi et al., 2015). Therefore, it might
be expected that c-Fos expression should be high in conditions
of chronic network hyperactivity. However, hippocampal c-Fos
expression is biphasic, increasing after acute neuronal activity
but decreasing in chronically active neurons (Calais et al.,
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2013; Renthal et al., 2008; Sheng and Greenberg, 1990;
Tsankova et al., 2004). The mechanisms governing such
biphasic regulation of c-Fos in the hippocampus are not clear.
Decreased hippocampal c-Fos expression in mouse models
of AD and epilepsy has been regarded as a potential contributor
to hippocampus-dependent cognitive deficits (Calais et al.,
2013; Palop et al., 2003, 2005; Chin et al., 2005; Espan˜a et al.,
2010). Therefore, it is critical to define the molecular mecha-
nisms responsible for reducing c-Fos expression.
DFosB is an activity-dependent transcription factor in the im-
mediate early gene family and is an alternatively spliced product
of the FosB gene. However, unlike the products of other imme-
diate early genes, such as c-Fos, DFosB has an unusually long
half-life that allows it to accumulate and remain in chronically
active cells for weeks (McClung et al., 2004; Nestler et al.,
2001). Studies ofDFosB function in the nucleus accumbens after
chronic exposure to drugs of abuse revealed that DFosB epige-
netically regulates a number of gene targets critical in addiction,
including c-Fos, via histone modifications (Renthal et al., 2008).
The term ‘‘epigenetic’’ is used here to indicate histone modifica-
tions that alter gene expression.
We therefore hypothesized that high levels of neuronal activity
induced by seizuresmay similarly lead to accumulation ofDFosB
in the hippocampus, where it would alter the expression of target
genes, such as c-Fos, causing long-term consequences for hip-
pocampal function. Indeed, in the hippocampus, overexpression
of DFosB can exert effects on learning and memory (Eagle et al.,
2015). In the present study, we examined expression ofDFosB in
a transgenic mouse model of AD neuropathology that exhibits
spontaneous seizures, and in a pharmacological model of epi-
lepsy. We demonstrate that seizure-induced DFosB expression
in the hippocampus is present and epigenetically suppresses
c-Fos expression in both models. Moreover, blocking either his-
tone deacetylation or DFosB activity ameliorated effects on both
c-Fos expression and memory impairment. Our results reveal
a molecular mechanism that explains why hippocampal c-Fos
expression is chronically reduced in conditions associated
with aberrant neuronal hyperactivity, and highlight potential ther-
apeutic avenues to improve cognitive function in both AD and
epilepsy.
RESULTS
Seizure-Induced DFosB Correlates with Impairments in
Hippocampal c-Fos Expression and Cognition in APP
Mice
Experimentally induced seizures can increaseDFosB expression
in the hippocampi of nontransgenic (NTG) wild-type mice (Chen
et al., 1997; McClung et al., 2004), but the consequences of such
increases on downstream gene expression are not clear. To
investigate a link between seizures, DFosB, and c-Fos in AD
mice, we first evaluated the relationship between seizures and
hippocampal DFosB expression in a commonly used transgenic
mouse model that expresses mutant human amyloid precursor
protein (APP) (line J20; Mucke et al., 2000). We performed elec-
troencephalogram (EEG) recordings in APP mice at 4–6 months
of age and found that the higher the frequency of epileptiform ac-
tivity or seizures in APP mice, the greater the increase in DFosB
expression levels in the dentate gyrus (DG) (Figures 1A and 1B).
Overall DFosB expression was higher in APP mice relative to
NTG controls, both by immunohistochemistry (Figure 1C) and
by western blot analysis (Figures S1A and S1B). To confirm
that DFosB expression in APP mice is driven by spontaneous
epileptiform activity, we treated NTG and APP mice with the
antiepileptic drug levetiracetam (75 mg/kg) for 14 days. Levetir-
acetam reduced epileptiform activity (Figure S2) consistent with
previous studies (Sanchez et al., 2012) and also reduced DFosB
expression in APPmice to levels that were no longer significantly
different from NTG mice (Figure 1D).
To determine whether such increased DFosB expression in
the DG is related to c-Fos expression, we confirmed our previous
findings of reduced c-Fos expression in the DG of APP mice
(Chin et al., 2005; Palop et al., 2005; Figures 1E and 1F). In addi-
tion, we observed that APPmice with the highest DFosB expres-
sion had the lowest numbers of c-Fos-immunoreactive (IR) cells
in the DG and that themagnitude ofDFosB and c-Fos expression
was inversely correlated in APP mice on both a mouse-by-
mouse and a cell-by-cell basis (Figures 1G and 1H). Because
c-Fos expression is tightly linked to spatial memory (Fleisch-
mann et al., 2003; He et al., 2002; Tischmeyer and Grimm,
1999), we examined whether DFosB expression levels in APP
mice were related to performance in the Morris water maze.
Indeed, the magnitude of DFosB expression correlated with
the distance to find the hidden platform in the water maze (Fig-
ure 1I). We also observed some variability in the water maze
performance of NTG mice (Figure 1I), which can sometimes be
randomly affected even in control conditions. There was no
obvious systematic relationship with DFosB levels, which did
not vary greatly in NTG mice.
The increase in DG DFosB expression is not restricted to the
particular line of APP mice used in our studies (line J20), as
Tg2576 and presenilin/amyloid precursor protein (PSAPP) mice
also exhibited increased DFosB-IR in the DG (Figures 1J, 1K,
S1E, and S1F). All of these lines of mice express human APP
with mutations linked to autosomal dominant AD, produce high
levels of Ab (Chin, 2011), and exhibit epileptiform activity (Chin
and Scharfman, 2013; Corbett et al., 2013; Kam et al., 2016;Min-
keviciene et al., 2009; Palop et al., 2007). Notably, similarly aged
I5A mice, which overexpress wild-type human APP and do not
produce high levels of Ab (Mucke et al., 2000), do not exhibit
increased DFosB (Figures 1L and S1G).
Epigenetic Mechanism of c-Fos Suppression in APP
Mice
DFosB suppresses c-Fos expression in nucleus accumbens by
directly binding to the c-Fos promoter and recruiting HDAC1,
thereby promoting deacetylation of histone H4 (Renthal et al.,
2008). We hypothesized that this mechanism could also be
responsible for the decreased c-Fos expression observed in
DG of APP mice. Indeed, chromatin immunoprecipitation
(ChIP) experiments demonstrated increased binding of DFosB
to the c-Fos promoter in the hippocampus of APP mice (Fig-
ure 2A). Interactions between DFosB and HDAC1 have been
characterized in nucleus accumbens (Renthal et al., 2008), and
co-immunoprecipitation experiments showed DFosB also binds
HDAC1 in the hippocampus (Figure 2B). Consistent with this,
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a target of HDAC1, histone H4, was hypoacetylated at the c-Fos
promoter in the hippocampus of APPmice (Figure 2C). No signif-
icant differences in histone H3 acetylation at the c-Fos promoter
were observed between NTG and APPmice (Figures 2D and 2E),
indicating relative specificity. Because histone H4 acetylation is
important for gene transcription (Grunstein, 1997; Lee et al.,
1993; Struhl, 1998; Tsankova et al., 2004), we measured c-Fos
mRNA in the hippocampus of NTG and APPmice and confirmed
that APP mice exhibited decreased levels of hippocampal c-Fos
mRNA compared to NTG controls (Figure 2F). Together, these
A B
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Figure 1. Epileptiform Activity and Seizures in APP Mice Were Associated with Increased DFosB and Decreased c-Fos in the Hippocampus
(A) EEG (upper panels) and corresponding immunohistochemical staining for DFosB (lower panels) in 4- to 6-month-old APP mice. A representative epileptiform
discharge in the shaded region in the middle set of traces is magnified on the right side of the panel. Electrodes were in left and right frontal cortex (L/RFC),
hippocampus (HIP), and parietal cortex (PC).
(B) Increased hippocampal DFosB immunoreactivity (IR) is associated with epileptiform activity and frequency of seizures (APP; n = 14).
(C) Increased DFosB IR in the DG of APP versus NTG mice (n = 12/genotype).
(D) 14-day treatment of APP mice with levetiracetam reduces DFosB IR (n = 4 or 5 per treatment/genotype; two-way repeated measures (RM) ANOVA with
Bonferroni post hoc tests).
(E) Images of c-Fos-IR in NTG and APP mice.
(F) Reduced number of c-Fos-IR cells in the DG of APP versus NTG mice (n = 16–18/genotype).
(G) Expression of DFosB and c-Fos is inversely related in the DG of APP mice (n = 19 mice).
(H) Expression ofDFosB and c-Fos is also inversely related in individual cells within the DG (n = 23 cells). Arrows indicate cells expressing primarily DFosB (green)
or c-Fos (red); arrowheads indicate cells expressing both DFosB and c-Fos (yellow).
(I) Average path length to find the hidden platform in the Morris water maze is associated with hippocampal DFosB expression (n = 21 or 22/genotype).
(J–L) Increased DFosB IR was detected in the DG of Tg2576 (n = 9 or 10/genotype) (J) and PSAPP mice (n = 5/genotype) (K), but not in I5A mice (n = 7–9/
genotype) (L).
AU, arbitrary unit. Data were normalized to NTG control values (rel to NTG). *p < 0.05; **p < 0.01; ****p < 0.0001. Error bars indicate SEM. See also Figures S1 and
S2 and Tables S3 and S4.
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data support the hypothesis that increased hippocampal DFosB
suppresses c-Fos expression in APP mice.
Pharmacologically Induced Seizures Are Sufficient to
Increase DFosB and Suppress c-Fos in NTG Mice within
Days
We next investigated whether seizures alone, outside of the
context of other AD-related factors, were sufficient to drive
DFosB-mediated c-Fos suppression and hippocampal memory
deficits in NTG mice. We assessed DFosB and c-Fos IR in the
DG of NTG mice given a single convulsant injection of kainic
acid (KA) or saline control and examined mice either 2 hr later
as seizures were occurring or 3 days later when seizures were
over. Mice injected with KA exhibited dose-dependent behav-
ioral seizures that were observed in the first 2 hr post-injection
(Figure S3A). For mice that were sacrificed 2 hr after KA injection,
high doses (15 and 25 mg/kg) of KA caused severe behavioral
seizures and increased levels of both DFosB and c-Fos
compared to saline-treated mice (Figures 3A, 3B, S1A, and
S1C), whereas no changes were observed in mice receiving a
low dose (5 mg/kg) of KA that did not elicit behavioral seizures.
Three days after KA injection, DFosB expression remained
increased in mice that received high doses of KA, consistent
with its long half-life, and was unchanged in mice that received
low doses of KA (Figures 3C, S1A, and S1D). DFosB expression
persisted for at least 4 weeks after KA injection (Figure S3B). At
3 days post-injection, low doses of KA increased c-Fos expres-
sion, whereas high doses of KA decreased c-Fos expression
(Figure 3D). The dose-dependent relationship between DFosB
and c-Fos expressionwas positively correlated 2 hr after KA (Fig-
ure 3E) but inversely correlated 3 days after KA (Figure 3F). These
results suggest that at 2 hr post-KA, DFosB had not yet sup-
pressed c-Fos expression; however, by 3 days post-KA, it had.
Therefore, induction of seizures in NTG mice appears to be suf-
ficient, after 3 days, to simulate the increased DFosB/decreased
c-Fos signature observed in the DG of APP mice. A summary of
the cellular changes following different seizure severities is pro-
vided in Figure 3G.
To determine whether the decreased c-Fos levels observed
in the DG of mice exposed to high doses of KA were also due
to DFosB-mediated epigenetic suppression, we performed
ChIP experiments. Three days after mice were administered
15 mg/kg KA, there was increased binding of DFosB to the Fos
promoter compared to saline-treated mice (Figure 3H) and also
decreased hippocampal Fos mRNA expression (Figure 3I).
We investigated whether the increased DFosB expression in
KA-treatedmice was also associated with hippocampal memory
deficits. We used the object location memory task, a hippocam-
pus-dependent spatial memory task (Faust et al., 2013; Scharf-
man and Binder, 2013). Mice received weekly injections of either
saline or KA (15 mg/kg) for 3 weeks to ensure maximal DFosB
expression and persistent decreases in c-Fos prior to behavioral
testing. Mice that received saline injections displayed intact
memory, but mice that received KA injections exhibited impaired
memory (Figure 3J). Together, these data support the hypothesis
that seizures are sufficient to driveDFosB-mediated suppression
of c-Fos and contribute to hippocampal memory deficits.
Persistent DFosB Expression Leads to Desensitization
of c-Fos Expression with Repetitive Seizures
c-Fos mRNA induction in the cortex is attenuated after repeated
neuronal stimulation by either brain injury or seizures (Calais
et al., 2013; Ivkovic et al., 1994; Renthal et al., 2008; Winston
et al., 1990).We hypothesized that, similar to the effect of chronic
exposure to drugs of abuse (Renthal et al., 2008), repeated sei-
zures may lead to desensitization of c-Fos expression due to
the upregulation and persistent presence of DFosB in the hippo-
campus. We therefore examined whether increased DFosB
expression coincidedwith desensitization of c-FosmRNA induc-
tion in the hippocampus following multiple KA injections. We first
verified the expression time course of c-Fos mRNA by injecting
NTGmice with a single dose of 15 mg/kg of KA and then assess-
ing levels of hippocampal c-Fos mRNA at various time points. As
expected, c-FosmRNAwas robustly increased 1 hr post-KA and
returned to baseline levels 4.5 hr post-KA (Figure 4A). We then
injected NTG mice with KA (15 mg/kg) either one, two, three,
A C D E FB
Figure 2. Epigenetic Suppression of the c-Fos Gene in the Hippocampus of APP Mice
(A) Increased DFosB binding to the c-Fos promoter in the hippocampus APP versus NTG mice (n = 8/genotype).
(B) DFosB co-immunoprecipitates (IP) with HDAC1 in the hippocampus of NTG and APP mice. Two exposures of the same DFosB blot are shown.
(C) c-Fos promoter is hypoacetylated on histone H4 in APP versus NTG mice (n = 7/genotype).
(D and E) No changes in tetra-acetyl histone H3 (n = 8/genotype) (D) or di-acetyl histone H3 (n = 8/genotype) (E) were detected in APP versus NTG mice.
(F) Reduced c-Fos mRNA expression in APP versus NTG mice (n = 12/genotype).
Data were normalized to NTG control values (rel to NTG). *p < 0.05; ***p < 0.001. Error bars indicate SEM. See also Tables S3 and S4.
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four, or five times, with injections spaced 4.5 hr apart for the first
four injections and 12 hr apart for the fourth and fifth injections.
Mice were sacrificed 1 hr following their final injection, and
hippocampal DFosB protein and c-Fos mRNA expression was
assessed. Increased expression of DFosB protein was first de-
tected after the second injection, and remained high throughout
the remainder of the protocol (Figure 4B), and coincided with
desensitization of c-FosmRNA expression (Figure 4C). These re-
sults support the hypothesis that persistent DFosB upregulation
can desensitize c-Fos expression to repeated stimulation. The
mean maximum seizure score in mice injected multiple times
with KA was lower than in mice injected only once (Figure S4A),
so other factors, such as modification of glutamate receptors
(Borbe´ly et al., 2009; Vila´gi et al., 2009), may also be involved
in attenuation of c-Fos induction and seizures scores. The multi-
ple KA injections did not result in any obvious cell death
(Figure S4B).
HDAC1 Contributes to the Suppression of Physiological
c-Fos Induction in the Hippocampus of APP Mice
Given that DFosB suppresses c-Fos expression during seizures,
we hypothesized that prolonged levels of DFosB might serve as
a persistent brake that limits c-Fos expression during physiolog-
ical neuronal activity. Indeed, APP mice exhibit impaired induc-
tion of c-Fos expression after exploration of a novel environment
(NE) (Palop et al., 2003), but the mechanisms were not clear.
Because DFosB binds HDAC1 in the hippocampus, and sup-
pression of c-Fos in the nucleus accumbens is dependent on
DFosB-mediated recruitment of HDAC1 to the c-Fos promoter
(Kennedy et al., 2013; Renthal et al., 2008), we predicted that
acute inhibition of HDAC1 would improve physiological c-Fos
induction.
To test this hypothesis, we treatedmicewith the class I histone
deacetylase (HDAC) inhibitor 4-phenylbutyric acid (4-PBA) 1 hr
prior to exposure to NE. After exploring the NE for 2 hr, mice
A B
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Figure 3. Pharmacologically Induced Seizures Are Sufficient to In-
crease DFosB and Suppress c-Fos in NTG Mice within Days
(A and B) At 2 hr after single administration of 15 or 25 mg/kg KA, there were
increases in DFosB IR (n = 4/group) (A) and c-Fos IR (n = 4/group) (B).
(C) DFosB IR is increased 3 days after single administration 15 or 25 mg/kg KA
(n = 4/group).
(D) c-Fos IR is increased 3 days after single administration of 5 or 10 mg/kg KA
but decreased 3 days after 15 or 25 mg/kg KA (n = 4/group).
(E) DFosB and c-Fos expression are positively correlated with increasing
doses of KA when assessed 2 hr after KA injection.
(F)DFosB and c-Fos expression are inversely correlated with increasing doses
of KA when assessed 3 days after KA injection.
(G) Summary of results from (A)–(D). ‘‘0’’ indicates no change from control,
whereas ‘‘+’’ and ‘‘’’ indicate increase and decrease from control, respec-
tively.
(H) Increased DFosB binding to the c-Fos promoter in mice 3 days after
15 mg/kg KA (n = 5/group).
(I) Decreased Fos mRNA expression in mice 3 days after 15 mg/kg KA (n = 8 or
9/group).
(J) NTG mice treated with three weekly doses of saline, but not 15 mg/kg KA,
show preference for the displaced object in the test phase of the object
location memory task (n = 6/group).
Data were normalized to saline-treated control values (rel to Sal). *p < 0.05;
**p < 0.01, ***p < 0.001. ns, non-significant. Error bars indicate SEM. See also
Figures S1 and S3 and Tables S3 and S4.
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were sacrificed and their brains processed to assess c-Fos-IR
cells in the DG. Mice treated with saline and/or left in their
home cages were used as controls. As expected, saline-treated
NTG, but not APP, mice exhibited a greater number of total
c-Fos-IR cells when exposed to the NE than when left in their
home cages (Figure 5A). Surprisingly, neither NTG nor APP
mice treated with 4-PBA 1 hr prior to placement in the NE ex-
hibited increased total numbers of c-Fos-IR cells compared to
their home cage controls (Figure 5B). We initially thought that
the lack of effect might be due to non-specific HDAC blockade,
because 4-PBA inhibits all class I HDACs (HDACs 1–3 and 8). To
inhibit HDAC1 more specifically, we treated NTG and APP mice
with MS-275, an inhibitor of HDAC1–3 that has a median inhibi-
tion concentration (IC50) that is 8- to 30-fold lower for HDAC1
than for HDACs 2 and 3 (Bahari-Javan et al., 2012; Hu et al.,
2003; Khan et al., 2008). The brain penetration of MS-275 has
also been characterized (Hooker et al., 2010; Simonini et al.,
2006), allowing us to administer a dose predicted to be near
the IC50 for HDAC1. However, similar to 4-PBA treatment, treat-
ment with MS-275 2 hr before placement in the NE did not in-
crease the total number of c-Fos-IR cells of NTG or APP mice
compared to home cage controls (Figure 5C).
A
B
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Figure 4. Persistent DFosB Expression Leads to Desensitization of
c-Fos Expression with Repetitive Seizures
(A) Hippocampal c-Fos mRNA expression in NTG mice is increased 1 or 2 hr
after single administration of 15mg/kg KA but returns to baseline at 4.5 hr (n = 3
or 4/group).
(B) DG DFosB IR was increased in mice that received multiple administrations
of 15 mg/kg KA.
(C) The increase in c-Fos mRNA expression after each KA injection is atten-
uated with multiple injections, which is first evident when DFosB expression
increases as shown in (B).
Data were normalized to saline-treated control values (rel to Sal). *p < 0.05;
**p < 0.01; ***p < 0.001. Error bars indicate SEM. See also Figure S4 and
Tables S3 and S4.
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Figure 5. Acute HDAC Inhibition Partially Restores c-Fos Induction
in APP Mice
(A) NTG, but not APP,mice exhibit increased total c-Fos IR in the hippocampus
after exploration of a novel environment for 2 hr (NE+) relative to home cage
controls (NE; n = 9 or 10/group).
(B and C) Neither NTG nor APP mice exhibit significant increases in the total
number of c-Fos IR cells when exposed to NE 1 hr after 4-PBA treatment (n = 6/
group) (B) or 2 hr after MS-275 treatment (n = 8–10/group) (C).
(D) In control conditions, NTG, but not APP, mice exhibit increased numbers of
c-Fos-IR cells above optical threshold when exposed to NE versus home cage
(n = 9 or 10/group).
(E and F) Both NTG and APP mice exhibit increased number of c-Fos-IR cells
above optical threshold when exposed to NE 1 hr after 4-PBA treatment (n = 6/
group) (E) or 2 hr after MS-275 treatment (n = 8–10/group) (F).
(G and H) Histone H4 acetylation on the Fos promoter in APP mice is
normalized after treatment with 4-PBA (n = 6/group) (G) or MS-275 (n = 6/
group) (H).
Data in (D)–(F) were normalized to NTG home cage control values (rel to
NTG/). *p < 0.05; ***p < 0.001. Error bars indicate SEM. See also Figures S5
and S6 and Tables S3 and S4.
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Because c-Fos is only expressed in a sparse population of DG
cells at baseline, we hypothesized that increases in physiologi-
cally induced c-Fos following HDAC inhibition might be detect-
able only in select granule cells that were highly active. Further-
more, because HDAC inhibition appears to increase the baseline
number of DG c-Fos-IR cells in home cage controls (Figures 5A–
5C), it was possible that the specific population of c-Fos-IR cells
induced during NE exploration was difficult to detect by total cell
counts. Therefore, we investigated whether acute HDAC inhibi-
tor treatment increased c-Fos IR in a specific population of DG
cells capable of inducing c-Fos at high levels. To do this, we
set an optical threshold during quantification so that only DG
cells with high c-Fos-IR were counted (Figure S5). Using this
quantification method, we found that saline-treated NTG mice
exposed to the NE exhibited higher numbers of c-Fos-IR cells
above threshold compared to home cage controls whereas sa-
line-treated APPmice did not demonstrate this effect (Figure 5D).
However, when treated with either 4-PBA or MS-275 prior to
placement in the NE, both NTG and APP mice that explored
the NE exhibited increased numbers of c-Fos-IR cells above
threshold compared to home cage controls (Figures 5E and
5F). To verify that treatment with 4-PBA and MS-275 inhibited
HDAC1, we confirmed that there were no significant differences
in hippocampal histone H4 acetylation at the c-Fos promoter
among any groups treated with 4-PBA or MS-275 (Figures 5G
and 5H). Moreover, no differences in the number of object inter-
actions during NE exploration were observed between NTG and
APPmice, regardless of treatment (Figures S6A–S6C), indicating
that the induction of c-Fos was not due to behavioral alterations.
We also confirmed that APP mice exhibited increased DFosB-IR
in the DG compared to NTG controls, regardless of treatment or
cage condition (Figures S6D–S6F). DFosB-IR was inversely
related to the number of c-Fos-IR cells above threshold in saline
and MS-275-treated APP mice and trended toward an inverse
relation in 4-PBA-treated APP mice (Figures S6G–S6I). More-
over, acute HDAC inhibitor treatment did not affect the number
of spikes observed by EEG recording, indicating that the alter-
ations in c-Fos expression were not due to gross changes in
EEG activity (Figure S6J). Together, these results demonstrate
that HDAC1 contributes to the suppression of physiological
c-Fos induction in the DG of APP mice.
Acute HDAC1 Inhibition Improves Hippocampus-
Dependent Memory Deficits in APP Mice
Physiological c-Fos induction is critical for hippocampal memory
(Fleischmann et al., 2003; He et al., 2002). Therefore, we hypoth-
esized that acute HDAC inhibition would also improve hippocam-
pal memory in APP mice if administered prior to training. We as-
sessed hippocampal memory using the object location memory
task because it could be completed within the same 2-hr time
frame as the NE paradigm. We treated mice with saline, 4-PBA,
orMS-275prior to training in the object locationmemory task. Sa-
line-treated NTGmice, but not APPmice, spent an increased per-
centage of time interacting with the displaced object during
testing compared to training. When treated with 4-PBA or MS-
275, both NTG and APP mice spent an increased percentage of
time interactingwith the displacedobject during the testing phase
(Figures 6A and 6B). We hypothesize that DFosB recruits HDAC1
to deacetylate its gene targets, and thus, HDAC1 functions down-
stream of DFosB. Therefore, inhibition of HDACs with either
4-PBA or MS-275 should not affect DFosB levels, especially
with the acute time frame of treatment, given that the half-life of
DFosB is 8 days. Consistent with our hypothesis, APP mice dis-
played increased levels of DFosB in the DG compared to NTG
controls, regardless of treatment (Figures 6C and 6D). Moreover,
acute treatment with HDAC inhibitors did not non-specifically
alter spiking frequency in APP mice (Figure S6J). These results
support the hypothesis that HDAC1 actively and acutely sup-
presses the expression of genes important for hippocampal
memory and contributes to cognitive deficits in APP mice.
Direct Inhibition of DFosB Improves c-Fos Induction and
Hippocampus-Dependent Memory in APP Mice
Our results suggest that direct inhibition of DFosB should also
improve DG c-Fos induction and spatial memory deficits in
A
B
C D
Figure 6. Acute HDAC Inhibition Improves Hippocampus-Depen-
dent Learning and Memory in APP Mice
(A and B) APP mice exhibited increased time interacting with the displaced
object during the test phase of the task, when, prior to training, they were
treated with either 4-PBA (n = 5 or 6/group) (A) or MS-275 (n = 6/group) (B)
relative to treatment with vehicle (control).
(C and D) Increased DFosB expression in APP versus NTG mice is unaffected
by 4-PBA (n = 5 or 6/group) (C) or MS-275 (n = 7/group) (D).
Data in (C) and (D) were normalized to vehicle-treated NTG values (rel to NTG/
Ctrl). *p < 0.05; **p < 0.01; ***p < 0.001. Error bars indicate SEM. See also
Tables S3 and S4.
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APP mice. To test whether this is true, we used DJunD, an
N-terminally truncated mutant of JunD, the normal binding part-
ner of DFosB. When expressed in neurons, DJunD serves as a
dominant-negative inhibitor of DFosB (Berton et al., 2007; Vialou
et al., 2010).
To achieveDJunD overexpression in theDG,we utilized an ad-
eno-associated virus serotype 2 (AAV2) delivery system (Vialou
et al., 2010). We confirmed DJunD overexpression in the DG
by stereotaxically infusing AAV2 carrying GFP alone (AAV-GFP)
into the left DG and AAV2 carrying both GFP and DJunD (AAV-
GFP/DJunD) into the right DG of NTGmice and assessed DJunD
expression at 28 days. Using an antibody that recognizes both
DJunD and endogenous JunD, we verified that AAV-GFP/DJunD
overexpressed DJunD by nearly 3-fold above endogenous JunD
levels (Figures 7A and S7).
To test whether DJunD overexpression improves hippocam-
pal memory and increases c-Fos expression in the DG of APP
mice, we infused either AAV-GFP or AAV-GFP/DJunD bilaterally
into the DG of NTG and APP mice and tested them in the object
location memory task 28 days later. NTG mice spent more time
interacting with the displaced object in the testing phase of the
task, regardless of treatment (Figure 7B). APPmice that received
AAV-GFP spent similar amounts of time with the displaced ob-
ject in both training and testing phases, demonstrating impaired
hippocampal memory (Figure 7B). However, APP mice that
received AAV-GFP/DJunD spent an increased percentage of
A C
D
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Figure 7. Direct Inhibition ofDFosB Signaling
Improves c-Fos Expression and Hippocam-
pus-Dependent Memory in APP Mice
(A) Unilateral AAV-GFP/DJunD infusion into the
right DG achieves robust DJunD overexpression in
comparison with AAV-GFP infused into the contra-
lateral side.
(B) Bilateral AAV-DJunD infusion into the DG of APP
mice improves performance in the object location
memory task.
(C) Bilateral AAV-GFP/DJunD (DJunD) infusion
into the DG of NTG and APP mice achieves robust
DJunD overexpression versus AAV-GFP (GFP)
control.
(D) DJunD overexpression does not impact DFosB
expression in APP mice.
(E) DJunD overexpression restores c-Fos expres-
sion in APP mice.
JunD/DJunD and DFosB quantification data were
normalized to AAV-GFP-treated NTG values (rel to
NTG/GFP). n = 5–8/group for (B)–(E). *p < 0.05; **p <
0.01; ***p < 0.001. Error bars indicate SEM. See also
Figure S7 and Tables S3 and S4.
time interacting with the displaced object
in the testing phase (Figure 7B), indicating
that DJunD overexpression improves hip-
pocampal memory in APP mice.
After behavioral testing, we verified that
JunD-IR was increased in NTG and APP
mice receiving AAV-GFP/DJunD infusion
(Figure 7C) and that DFosB expression
was increased in APP mice regardless of
the type of virus infused (Figure 7D). We then quantified the total
number of c-Fos-IR cells in the DG of NTG and APP mice
receiving AAV infusions. DJunD overexpression did not affect
c-Fos expression in the DG of NTGmice. APPmice that received
AAV-GFP/DJunD exhibited increased numbers of c-Fos-IR cells
in the DG compared to APP mice that received AAV-GFP (Fig-
ure 7E). This result indicates that DFosB directly mediates the
suppression of c-Fos expression in the DG of APP mice.
DISCUSSION
A growing body of evidence suggests that network dysfunction
in the form of epileptiform activity contributes to cognitive defi-
cits in AD, even in early stages of the disease (Bakker et al.,
2012; Vossel et al., 2013, 2016). Understanding how specific
neuronal alterations contribute to cognitive deficits may there-
fore highlight additional therapeutic avenues to improve the
quality of life for AD patients. Moreover, because long-term
treatment with antiepileptic drugs is associated with many
adverse effects, targeting more specific mechanisms may
enable development of treatments with fewer side effects.
Our studies reveal a molecular mechanism by which epilepti-
form activity might contribute to cognitive deficits in AD and ep-
ilepsy. This mechanism highlights seizure-induced DFosB as a
transcription factor that critically regulates hippocampal mem-
ory, although other effects of seizures and/or APP/Ab may also
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play a role. Due to the unusually long half-life of DFosB, even
infrequent epileptiform activity would be sufficient to maintain
persistent high levels of DFosB. Therefore, DFosB is well poised
to modulate gene expression over extended periods of time,
which may be part of why cognitive deficits persist even during
seizure-free periods in AD and epilepsy patients, as well as in
relevant mouse models.
A critical implication of DFosB-mediated c-Fos suppression is
that it also explains the biphasic expression curve of c-Fos
expression after sustained high levels of neuronal activity. Hip-
pocampal c-Fos expression is increased by acute neuronal ac-
tivity but decreased by chronic activity (McClung et al., 2004;
Renthal et al., 2008; Sheng and Greenberg, 1990; Tsankova
et al., 2004). The gradual but persistent nature of activity-
induced DFosB expression directly accounts for the biphasic
expression profile of c-Fos. Acute neuronal activity induces
c-Fos expression prior to the accumulation of DFosB to high
enough levels in the nucleus to regulate gene expression.
Following chronic neuronal activity, persistent increases in
DFosB allow it to reach a threshold that enables regulation of
genes, such as c-Fos. Therefore, although c-Fos expression is
frequently used as a marker of neuronal activity, it may only
accurately reflect activity under acute conditions. However, the
simultaneous use of both DFosB and c-Fos as activity markers
provides a more accurate readout of neuronal activity.
We focused on DFosB-mediated suppression of hippocampal
c-Fos expression as amechanism for hippocampal memory def-
icits. However, the extent to which the normalization of other
DFosB-targeted genes contribute to cognitive improvement
was not investigated. We chose to investigate DFosB-mediated
c-Fos suppression because the role of c-Fos in synaptic plas-
ticity and hippocampal memory is well established (Fleischmann
et al., 2003; He et al., 2002; Tischmeyer and Grimm, 1999).
Furthermore, DFosB may not be the sole mechanism underlying
hippocampal c-Fos suppression in APP mice. Other factors,
such as altered regulation of CREB-regulated transcription co-
activator-1 (Espan˜a et al., 2010; Saura, 2012; Yiu et al., 2011)
and increased levels of miR-181 (Rodriguez-Ortiz et al., 2014),
have also been implicated in reduced c-Fos expression ex-
hibited by mouse models of AD.
We hypothesized that DFosB actively suppresses the expres-
sion of genes important for cognition in the hippocampus and
that even a temporary relief of this suppression would improve
hippocampal memory. Indeed, acute HDAC inhibition improved
hippocampal c-Fos induction and hippocampal memory in APP
mice. Although acute HDAC inhibition may have improvedmem-
ory in APPmice by altering the expression of many genes impor-
tant for cognition in addition to c-Fos, the increase in c-Fos is
likely to have contributed strongly to the efficacy of acute
HDAC inhibition. Chronic treatment with class 1 HDAC inhibitors,
including 4-PBA, improved learning and memory in APP mice
(Kilgore et al., 2010; Ricobaraza et al., 2009), but our results
demonstrate that even a temporary relief of gene suppression
can improve cognition when administered prior to training in a
memory paradigm. For AD patients, acute treatment options
may minimize side effects by allowing for an infrequent but
well-timed schedule of administration (e.g., during family visita-
tion), thus improving overall quality of life.
Acute HDAC inhibition did not increase the total number of
c-Fos-IR cells in the DG of APP mice following exploration in
the NE paradigm; however, it did increase c-Fos expression in
a certain population of neurons. As such, it is possible that acute
HDAC inhibition is unable to affect more severe and/or chronic
epigeneticmechanisms thatmay have occurred, such as histone
or DNA methylation. Overexpression of DJunD, a more chronic
treatment thatmight altermultiplemodes of epigeneticmodifica-
tion, was able to improve the total number of c-Fos-IR neurons in
the DG of APP mice, lending support for this hypothesis.
Understanding how network dysfunction induces neuronal
alterations that cause cognitive deficits emphasizes the impor-
tance of the role that seizures play in AD. Furthermore, many dis-
eases, including schizophrenia (Hyde and Weinberger, 1997),
autism (Viscidi et al., 2013), Down syndrome (Lott et al., 2012),
fragile X syndrome (Hecht, 1991), Rett syndrome (Jian et al.,
2006), and Angelman syndrome (Pelc et al., 2008), are all accom-
panied by both seizures and cognitive deficits. Therefore, it is
possible that seizures and network dysfunction may be common
denominators contributing to cognitive deficits inmany brain dis-
orders. In addition, seizure-induced increases in DFosB may
contribute to deficits in cognition or other behaviors via alteration
of downstream gene targets that are already vulnerable due to
compromised genetic backgrounds.
EXPERIMENTAL PROCEDURES
Mice
4- to 6-month-old heterozygous transgenic and NTG mice from lines hAPP-
J20, Tg2576, and PSAPP were used in these experiments. Male and female
mice were used unless otherwise specified, and sex was balanced within a
cohort. All mice referred to as APP mice were of the line hAPP-J20, which ex-
press a human APP (hAPP) gene carrying Swedish (K670N andM671L) and In-
diana (V717F) familial AD mutations under control of the platelet-derived
growth factor b-chain promoter, on a C57BL/6 background (Mucke et al.,
2000). Tg2576 mice express hAPP carrying the Swedish familial autosomal
dominant (FAD) mutation (Hsiao et al., 1996). PSAPP mice express hAPP car-
rying the Swedish mutation and presenilin-1 with FAD mutation (M146L; Hol-
comb et al., 1998). For brain harvesting, mice were flush-perfused transcar-
dially with diethyl pyrocarbonate (DEPC)-treated saline. Hemibrains were
frozen on dry ice for biochemistry or postfixed in 4% paraformaldehyde for
immunohistochemistry. All procedures were approved by the Thomas Jeffer-
son University and Baylor College of Medicine Institutional Animal Care and
Use Committees.
Drug Treatment
Levetiracetamwas dissolved in saline at 15 mg/mL and administered intraper-
itoneally (i.p.) at a dose of 75mg/kg every 8 hr for 14 days. KA (Sigma) was dis-
solved in saline at 2 mg/mL and administered i.p. at doses described in Re-
sults. 4-PBA (Aldrich) was dissolved with equimolar NaOH in ddH2O to
0.125 M and injected i.p. at a dose of 200 mg/kg 1 hr prior to NE or object
placement paradigms. A stock solution of 50 mg/mL MS-275 in DMSO was
dissolved into a working solution of 1.5 mg/mL MS-275 in saline containing
20% DMSO, which was administered at 6 mg/kg via subcutaneous injection
2 hr prior to NE or object placement paradigms.
KA Injections and Seizure Severity Scoring
NTG mice were injected with KA IP at specified doses and monitored for 2 hr.
Seizure severity and elapsed times since injection were recorded using a
modified Racine scale (Racine, 1972; Roberson et al., 2007): 0, normal
behavior; 1, immobility; 2, generalized spasm, tremble, or twitch; 3, tail exten-
sion; 4, forelimb clonus; 5, generalized clonic activity with loss of posture; 6,
bouncing or running seizures; 7, full tonic extension; and 8, death. Acute KA
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groups were sacrificed 2 hr following a single KA injection (15 mg/kg). Sub-
chronic KA groups were sacrificed 3 days following a single KA injection
(15 mg/kg). For mice receiving multiple KA injections, all injections were sepa-
rated by 4.5 hr except for the fourth and fifth injections, which were separated
by 12 hr. Unless otherwise specified, mice were sacrificed 0.5 hr following their
final injection.
Video-EEG Monitoring
Electrodes were implanted as described in Supplemental Experimental Pro-
cedures. EEG recordings were performed on at least 2 different days for amin-
imum of 4 hr each using a Stellate Harmonie acquisition system. EEG signal
processing was performed using native Stellate software and Labchart Pro
(AD Instruments). The frequency and total number of spikes for each mouse
was analyzed.
AAV-Mediated Gene Transfer
AAV2 carrying CMV-DJunD-IRES2-eGFP (AAV-GFP/DJunD) or CMV-eGFP
(AAV-GFP) was previously described (Berton et al., 2007; Vialou et al., 2010),
demonstrating that these constructs are neurotropic and achieve stable
neuronal gene expression within 18–22 days of infusion into the brain. One
microliter of virus solution was stereotaxically infused unilaterally or bilaterally
into the hippocampus at rostral (1.7 mm anterior/posterior [A/P], 1.2 mm
medial/lateral [M/L], and 2 mm dorsal/ventral [D/V] from bregma) and caudal
(2.7mmA/P, 2mmM/L, and 2.1mmD/V from bregma) coordinates. Approx-
imately 23 108 infectious particles were infused into each hippocampus. Mice
were allowed to recover for 28 days post-surgery before behavior testing/
sacrifice.
Morris Water Maze
Female NTG and APP mice (4–6 months old; 20–24/genotype) were tested as
described in detail in the Supplemental Experimental Procedures. Mice were
first tested in cued platform sessions, two trials per day for 2 days. Hidden plat-
form training involved six trials/day over 7 days. After the last training trial, the
platform was removed and mice were given a 60-s probe trial test. Perfor-
mance was video tracked and analyzed using TopScan (CleverSys). The
experimenter was blinded to genotypes during testing.
Object Location Memory Task
The object locationmemory taskwas based on previously described protocols
(Scharfman and Binder, 2013) and is described in detail in the Supplemental
Experimental Procedures. Briefly, mice were trained in three trials to recognize
set locations of two identical objects in an empty mouse cage, and the time
spent exploring each object during each of the three trials was recorded. After
a 2-hr delay, the mouse was placed back in the test cage, in which one of the
objects had been displaced. The time spent exploring the displaced versus the
non-displaced object was recorded. For HDAC inhibitor treatments, training
began 1 hr following i.p. injection with saline or 4-PBA or 2 hr following subcu-
taneous injection with 20% DMSO in saline or MS-275. For KA experiments,
mice were injected with saline or 15 mg/kg KA once a week for 3 weeks and
trained/tested 3 days following the third injection.
Novel Environment
Female NTG and APP mice were placed in a NE either without treatment, 1 hr
following 4-PBA treatment, or 2 hr following MS-275 treatment. Home cage
control mice for each group received the same treatment in close temporal
proximity. The home cages of mice contained only bedding, a water bottle,
and a food hopper. The NE cage included a novel bedding material, a banana
slice, the grid of a pipette tip rack, a 50-mL conical vial cap, and a repeat pi-
petter tip wrapped in red tape. The top of the cage lid was removed for obser-
vation. Mice explored the NE for 2 hr while being video monitored and were
then sacrificed. The number of object interactions was quantified for each
mouse in 10-min bins at 1, 50, and 110 min into the recording.
Immunohistochemistry
Tissue preparation and immunohistochemistry were performed as described
(Chin et al., 2005; Corbett et al., 2013). Brains were sectioned at 30 mm. Anti-
bodies are listed in Table S1. For staining with 3,30-diaminobenzidine (DAB),
further amplification was accomplished using Avidin-Biotin Complex (Vectas-
tain). DAB (Sigma) was used as a chromagen. DFosB-IR quantification was
performed by assessing the mean pixel intensity using ImageJ software.
Quantification of c-Fos was performed by total cell count or by using the
threshold function provided by Metamorph. A pixel intensity threshold was
set such that 40–50 (30% of total) cells were above threshold in the DG
of NTG mice from the homecage group. This threshold was used for all
mice, and the number of c-Fos-IR cells above threshold was recorded. For
immunofluorescence, Metamorph software was used to quantify optical den-
sity throughout the rostral-caudal extent of the DG.
Western Blot
Western blot analysis was performed as described (Corbett et al., 2013). The
hippocampus from one hemibrain of each mouse was isolated and homoge-
nized with a Polytron tissue homogenizer in ice-cold radioimmunoprecipitation
assay (RIPA) buffer. Equal amounts of protein were resolved by SDS-PAGE on
4%–12% gels, transferred to nitrocellulose, and probed with primary anti-
bodies listed in Table S1. IR-dye-conjugated secondary antibodies were
used for detection and quantification using a LI-COROdyssey infrared imaging
system.
Co-immunoprecipitation
Hippocampi were lysed in immunoprecipitation buffer (320 mM sucrose,
10 mM Tris-HCl [pH 7.4], 10 mM EDTA, and 1% sodium deoxycholate) and
diluted 1:5 in binding buffer (150 mM NaCl, 50 mM Tris-HCl [pH 7.4],
0.5 mM EDTA, and 0.5% Triton-X). 4 mg of rabbit anti-HDAC1 (Abcam) was
added to immunoprecipitate HDAC1 prior to western blot analysis. HDAC1
and FosB were immunoblotted.
RNA Extraction
RNA extraction was adapted from instructions from the QIAGEN RNeasy kit.
Briefly, hippocampi were homogenized in RLT/b-mercaptoethanol buffer by
passing the lysate through an 18Gneedle followedby a 25Gneedle. After centri-
fugation, RNA was extracted and eluted with nuclease-free water. Final RNA
concentration was measured using a NanoDrop 2000 spectrophotometer.
qRT-PCR
Reverse transcription was performed using the Taqman Gold RT-PCR kit
(ABI). qPCRwas performed with an ABI 7500 PCRmachine using SYBRGreen
as a fluorophore. Primers used to amplify cDNA are listed in Table S2.
Chromatin Immunoprecipitation
ChIP was performed similarly to described methods (Renthal et al., 2008;
Tsankova et al., 2004). Hippocampi were subdissected and fixed in 1%
formaldehyde. Samples were sonicated to generate genomic fragments
200–1,000 bp in length and pre-cleared with Protein A beads (Millipore) prior
to incubation with antibodies listed in Table S1 at 4C overnight. The anti-
body-chromatin complex was immunoprecipitated with Protein A beads,
washed with a series of buffers (Millipore), and then chromatin was eluted
and reverse cross-linking performed with Proteinase K. DNA was purified via
phenol-chloroform extraction. Final DNA concentration was measured using
the NanoDrop 2000. qPCR was performed with an ABI 7500 PCRmachine us-
ing SYBR green as a fluorophore. Primers used to amplify the c-fos promoter
and b-actin promoter are listed in Table S2.
Statistical Analysis
Statistical analyses were performed using Prism 5. Raw values for data
presented as ‘‘relative to NTG controls’’ are listed in Table S3. Differences be-
tween means were assessed using a two-tailed, unpaired Student’s t test
unless otherwise indicated. Differences among three or more means were as-
sessed using one-way ANOVA and Tukey post hoc tests. Two-way ANOVA us-
ing Bonferroni or Student-Newman-Keuls post hoc tests were used to assess
differences in analyses with two variables. Repeated-measures two-way
ANOVA with Bonferroni post hoc tests were used for analyzing object location
memory data. Regression analysis was used to detect correlations. To assess
the relationship between c-Fos-expressing cells andDFosB expression, c-Fos
cell counts were log transformed in order to perform a linear regression and
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test for statistical significance. Detailed results of all statistical analyses are
listed in Table S4.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
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